Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose (Rimonabant 20 mg) Multicenter Study of Long-Term Glycemic Control With Rimonabant in Treatment-naive Patients With Type 2 Diabetes.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Rimonabant (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms SERENADE
- Sponsors Sanofi
- 01 Nov 2008 Results published in Diabetes Care.
- 01 Nov 2008 Primary endpoint 'Proportion of glycosylated haemoglobin' has been met according to results published in Diabetes Care.
- 03 Oct 2006 Status change